Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06599229
NCT06599229
Active, not recruiting
Not Applicable

Myocardial Perfusion Abnormalities in Hypertrophic Cardiomyopathy

University of Virginia1 site in 1 country30 target enrollmentStarted: January 2, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHypertrophic Cardiomyopathy (HCM)
Interventionsmyocardial contrast echo

Overview

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
30
Locations
1
Primary Endpoint
Peak hyperemic perfusion
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of hypertrophic cardiomyopathy
  • •Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

Exclusion Criteria

  • •Pregnancy
  • •Lactation
  • •Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
  • •Serious AE to regadenoson
  • •Hypotension
  • •Serious bradycardia not addressed by pacemaker
  • •Moderate or greater reactive airways disease

Arms & Interventions

Patients with HCM initiated on cardiac myosin inhibitor therapy

Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.

Intervention: myocardial contrast echo (Diagnostic Test)

Outcomes

Primary Outcomes

Peak hyperemic perfusion

Time Frame: 3 months

Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)

Secondary Outcomes

  • Resting myocardial perfusion(3 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jonathan Lindner, MD

Professor of Medicine

University of Virginia

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Myocardial perfusion and microvascular dysfunction in stable coronary artery disease during hyperoxaemia
ISRCTN67819491niversity of Leeds (UK)90
Completed
Not Applicable
Association Between Microvascular Resistance and Outcomes in Patients With Obstructive Hypertrophic CardiomyopathyMicrovascular DysfunctionHypertrophic Obstructive CardiomyopathyMicrocirculation Resistance
NCT05671367China National Center for Cardiovascular Diseases340
Recruiting
Not Applicable
Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MIMyocardial InfarctionCoronary StenosisCoronary Microvascular Dysfunction
NCT06376630National Medical Research Center for Cardiology, Ministry of Health of Russian Federation300
Completed
Not Applicable
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathyHypertrophic Cardiomyopathy
NCT02994615Lawson Health Research Institute19
Unknown
Not Applicable
Myocardial Contrast Echocardiography in Septic PatientsSepsisMicrocirculation
NCT04397640Universitair Ziekenhuis Brussel100